Elli Papaemmanuil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elli Papaemmanuil has a total of 872 co-authors. Here are the top co-authors by number of shared publications:
- Elsa Bernard
Inserm U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France
122 shared publications - Eva Hellström-Lindberg
Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institute, Huddinge, Sweden
113 shared publications - Luca Malcovati
Policlinico San Matteo Pavia Fondazione IRCCS, Pavia, Italy, Italy
113 shared publications - Maria Creignou
Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden
113 shared publications - Tetsuichi Yoshizato
Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
90 shared publications - Magnus Tobiasson
Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden
88 shared publications
Latest Publications
- Open Access
- 28 September 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (10) , 2579-2589
Germline homologous recombination deficiency influences TP53-mutant clonal hematopoiesis fitness during platinum and PARP inhibitor treatment
- 28 September 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (10) , 2579-2589
Open AccessGermline homologous recombination deficiency influences TP53-mutant clonal hematopoiesis fitness during platinum and PARP inhibitor treatment
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Optimization efforts to procure patient tumors, establish PDX tumor models and cryopreserve PDX tumor specimen.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Optimization efforts to procure patient tumors, establish PDX tumor models and cryopreserve PDX tumor specimen.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Comparative analysis of mutations in patient source tumors and corresponding PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Comparative analysis of mutations in patient source tumors and corresponding PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Validation of a EPB41L2::RAF1 gene fusion in an osteosarcoma PDX model.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Validation of a EPB41L2::RAF1 gene fusion in an osteosarcoma PDX model.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Evaluation of the EPB41L2::RAF1 gene fusion as an oncogenic driver and therapeutic target in osteosarcoma PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Evaluation of the EPB41L2::RAF1 gene fusion as an oncogenic driver and therapeutic target in osteosarcoma PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of sarcoma patient tumors and corresponding PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of sarcoma patient tumors and corresponding PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of osteosarcoma patient tumors and corresponding PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of osteosarcoma patient tumors and corresponding PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of neuroblastoma patient tumors and corresponding PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of neuroblastoma patient tumors and corresponding PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of Other Tumor cohort and corresponding PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of Other Tumor cohort and corresponding PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Molecular characterization of sarcoma PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Molecular characterization of sarcoma PDX models.